Immune-checkpoint blockade (ICB) can achieve durable benefit in advanced renal cell carcinoma (aRCC), but reliable biomarkers are lacking. Lisa Kinget, medical oncology resident at UZ Leuven, summarized her PhD research that was presented as poster at ESMO. She performed a comprehensive biomarker discovery in the aRCC transcriptomic dataset of ICB treated patients with corresponding human leukocyte antigen genotypes to characterize antigen presenting features. Multi-omics analysis revealed critical importance of antigenic myeloid-T cell crosstalk, driven by high neo-antigenicity, to ensure adequate ICB response in aRCC.
With the educational support of:
 |  |  |